Similar to the results of our previous meta-analysis, no significant differences were observed in progression-free survival (Log-rank, Chi-square, P=0.2593) or castration-resistant prostate cancer-free survival (Log-rank, Chi-square, P=0.3991) between the CRP and RT groups. The gene discussed is CRP; the disease is prostate carcinoma.